744 Views | 0 Downloads
Correspondence: Jonathan D. Glass, Department of Neurology, Emory University School of Medicine, Emory University, Atlanta GA. Email: jglas03@emory.edu.
The authors thank the patients and families of the Emory ALS clinic and the staff of the Emory ALS clinic, specifically Nicole Yarab, RN, and Meraida Polak, RN, BSN, for their assistance and contribution to the clinical database.
Content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
K. Traxinger and C. Richards report no disclosures.
Supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454.
B.A. Johnson serves as a consultant for MANILA Consulting Group, Inc., and receives research support from the NIH (P30AI50409-14, R21ES020225-02, CA168930-01, and 60032445 [sub-contract with Northwestern University]) and from the US Department of Defense (IDEA Award PC093328).
R.H. Lyles receives salary/research support from the NIH (1 RC4 NR012527-01, 5 R01 ES012458-07, and 5 UL1RR025008-04).
J.D. Glass is author on a patent re: Ketoamide calpain inhibitors for peripheral neuropathy and receives research support from Neuralstem, Inc., the NIH (NINDS and NIA), the Packard Center for ALS Research, and the Muscular Dystrophy Association.
© 2013 American Academy of Neurology